New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:59 EDTPRANPrana Biotechnology mentioned cautiously at Summer Street
Summer Street said it believes Prana Biotechnology 's PBT2 is a "long shot" as a treatment for Alzheimer’s and Huntington’s diseases. The firm is skeptical about PBT2's proposed mechanism. Shares of Prana are trading down 57c to $9.35 in pre-market trading.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PRAN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use